

**HDRUK**  
Health Data Research UK



**HSC** Public Health Agency  
Research and Development

**NICOR**



**Public Health Scotland**

**NHS Digital**

**SAIL DATABANK**

**UK Health Data Research Alliance**

**Office for National Statistics**



**epcc**

# COVID-19 Health Data Research

23 March 2021 - Fortnightly update for SAGE, National Core Studies & UKRI/DHSC

## Authors:

Alice Turnbull, Health Data Research UK  
Andrew Morris, Health Data Research UK  
David Seymour, UK Health Data Research Alliance  
Caroline Cake, Health Data Research UK (lead)  
Sinduja Manohar, Health Data Research UK  
Susheel Varma, Health Data Research UK  
Cathie Sudlow, BHF Data Science Centre  
Sophie Morris, Health Data Research UK  
Ashleigh Smith, Health Data Research UK  
Hollydawn Murray, Health Data Research UK  
James Pickett, Health Data Research UK  
Lara Edwards, Health Data Research UK  
Melissa Lewis-Brown, Health Data Research UK

John Deanfield, NICOR  
Mark Parsons, Scotland National Safe Haven  
Charlie Davie, DATA-CAN  
Members of the HDR UK Public Advisory Board & COVID-19 PPIE Group  
Ming Tang, NHS England and Improvement  
Nilesh Samani, British Heart Foundation  
National Core Study Programme Leads  
Pete Stokes, Office for National Statistics  
Ronan Lyons, SAIL Databank (UKRI/DHSC sponsor)  
Carole Morris, Public Health Scotland  
Garry Coleman, NHS Digital  
Ian Young, Health & Social Care Northern Ireland



## Health data research community highlights this period



**32** COVID-19 taskforce calls with **183** clinical and health data research leaders engaged



**1,193** COVID-19 pre-print publications



**779** academic, industry and NHS participants in COVID-19 Slack channel with 10 sub-channels



**111** health data research questions identified



### Patient and Public Voice Feedback:

Following a year since the introduction of the first lockdown, whilst significant advances have been made, we must not lose momentum especially given the number of unanswered research questions that remain, particularly around:

- Vaccines – effectiveness in different populations, effect on transmission rates and factors that influence vaccine uptake.
- COVID-19 has shown to affect referral, diagnosis and treatment, particularly in cardiovascular disease and cancer – to what extent does this affect other health conditions too and are particular groups and populations are affected more than others?
- After being in a range of restrictions for a year, whilst we start to move out of it on a long-term basis, this change could cause mental health problems and further research is needed to understand the true extent to better prepare services for the coming months.

Click [here](#) to read more feedback



Click [here](#) for a list of regularly updated COVID-19 research questions from the health data community

# Research topics with new insights generated in last 2 weeks

Health data research outputs on COVID-19 continues to grow, now reaching 1,193 (+16) non-peer-reviewed pre-prints & 125 (+5) published papers.

| Topic                                      | Insights from ongoing studies (links provide further details):  |
|--|---|
| <b>Surveillance &amp; Epidemiology</b>     | <ul style="list-style-type: none"><li>Data from &gt;2000 participants of the Genetics Of Mortality In Critical Care (GenOMICC) and the Coronavirus Clinical Characterisation Consortium (ISARIC 4C) studies indicate that <a href="#">a common variant of a transmembrane protein occurring in ~25% of the population is associated with a reduced likelihood of developing severe COVID-19</a> – suggesting that this could be a promising drug target in the treatment of COVID-19.</li><li>Using patient-level data from more than 2000 patients from the CAPACITY-COVID project, researchers found <a href="#">the incidence of acute ischemic stroke in patients hospitalised with COVID-19 was ~2%, and patients with COVID-19 and stroke were twice as likely to have a blood clot in the lungs</a> – indicating an urgent need for further research.</li><li>Using primary care records, latest research on drugs commonly used to treat high blood pressure, provides reassurance that <a href="#">angiotensin-converting enzyme I (ACE) inhibitors are safe to use during the pandemic- whereas angiotensin II receptor blockers (ARBs) were associated with a small increase in risk of COVID-19</a>.</li><li>Research combining surveillance data from the UK Zoe COVID Symptom Study and the UK UMD-Facebook COVID-19 Symptom Survey found <a href="#">25% of individuals with symptoms do not get tested</a>; improved public health messaging around symptoms and test sites may address this gap.</li></ul> |
| <b>Immunity &amp; Vaccines</b>             | <ul style="list-style-type: none"><li>New findings from Public Health England’s routine testing of NHS Blood and Transplant blood donations show that <a href="#">70-84 year olds are mounting a good immune response to a single vaccine dose</a>; 75.8% of older adults had COVID-19 antibodies and only 5.6% were from natural infection.</li><li>Analyses of linked patient-level data for &gt;17 million people in England indicate that <a href="#">people with learning disabilities are more likely to be hospitalised and die from COVID-19; and the risk is higher for people with Down Syndrome and Cerebral Palsy</a>. These data highlight the importance of updating learning disability registers and reinforce the UK’s recent policy change to prioritise all people with learning disabilities for vaccination.</li><li>A longitudinal study of &gt;13,000 vaccinated healthcare workers shows <a href="#">2 doses of vaccine provide levels of protection similar to natural immunity, including against the UK variant</a>; whilst a study linking multiple health and occupational records of 144,525 NHS Scotland healthcare workers and 194,362 of their household members found that <a href="#">vaccination of healthcare workers substantially reduced COVID-19 cases in household contacts</a> – suggesting that vaccination reduces transmission.</li></ul>   |
| <b>Longitudinal health &amp; wellbeing</b> | <ul style="list-style-type: none"><li><a href="#">Researchers using NHS England's Monthly Diagnostic Waiting Times and Activity data detected a marked reduction in endoscopic procedures such as colonoscopies during the pandemic</a>. Models suggest that even with mitigation measures in place it could take more than a year to clear this backlog.</li></ul>   |
| <b>Transmission &amp; Environment</b>      | <ul style="list-style-type: none"><li>Analyses of antibody tests linked to national SARS-CoV-2 testing programme data from &gt;2000 staff and residents across 100 long term care facilities in England as part of the VIVALDI study, suggest that <a href="#">antibodies provide high levels of protection against reinfection</a>.</li><li>Researchers monitoring &gt;180,000 hospital discharge events in the first wave using individually linked health records from the SAIL Databank found that <a href="#">hospital discharge to care homes played a minor role in COVID-19 transmission</a>. Estimates suggest ~1.8% of patients discharged from hospital may have been infected.</li><li>Analyses of NHS Test and Trace data alongside genomic data from the COVID-19 Genomics UK (COG-UK) consortium revealed that <a href="#">travel restrictions are effective in reducing onwards transmission of COVID-19</a>. The use of genomics in monitoring travel-related cases is important as the government considers reopening the borders for holidays.</li></ul>   |
| <b>Clinical Trials</b>                     | <ul style="list-style-type: none"><li>The most recent results from the Randomised Evaluation of COVid-19 thERapY (RECOVERY) trial involving 11,558 patients indicate that <a href="#">convalescent plasma does not improve survival in patients hospitalized with COVID-19</a>. These results were consistent across subgroups of patients, including people of different ages and ethnicities.</li></ul>   |

# Data & Connectivity National Core Study: COVID-19 dataset availability – 23 March

Vaccine data now available for Wales and England and will soon be available for Scotland. Viral genome data also soon to be available for Scotland.

**KEY**

1. Custodian engagement

2. Dataset available in secure Trusted Research Environment

3. Linkages established to other priority datasets (within TRE)

4. Datasets available for COVID-19 research via Gateway

Further information about **Data & Connectivity** can be found [here](#). Including the recently published **Sprint 5 report**.

Linked census, mortality and hospital episode statistics now available as a joint data asset between ONS and NHSD

| Core COVID-19 Datasets available for linkage   | Office for National Statistics<br>Secure Research Service                   | England<br>(NHS Digital Data Processing Service)  | Scotland<br>(National Data Safe Haven)  | Wales<br>(SAIL Databank)   | Northern Ireland<br>(Honest Broker Service)                                      |
|--|---|---|---|--|--|
| C-19 vaccine data collection                   | To be made available shortly. Accepting applications now                    | Vaccines Events & Adverse Reactions   | Available in TRE, available via Gateway shortly.                                  | COVID Vaccination Dataset  | Vaccine Management System Operational – Data to be transferred to Data warehouse |
| COG-UK viral genome                            | Awaiting data flow from Public Health England                               | Awaiting data flow from Public Health England   | Subset linked to CO-CIN data Remaining data being transferred, available shortly. | Awaiting data flow from Public Health Wales  | Governance agreed, automation of data flow to PHA in progress                    |
| Pillar 1 COVID-19 Testing Data                 | To be linked to Test and Trace data   | COVID-19 Second Generation Surveillance System (SGSS)   | Electronic Communication of Surveillance in Scotland (ECOSS)                      | COVID-19 Test Results  | COVID antigen testing - Pillar 1   |
| Pillar 2 Testing data (UK Gov)                 | To be linked to Test and Trace data   | COVID-19 UK Non-hospital Antigen Testing Results (Pillar 2)                                   | Electronic Communication of Surveillance in Scotland (ECOSS)                      | COVID-19 Test Results  | Missing results prior to 26 Apr – Data quality issue                             |
| Primary Care                                   | GPES linked to census, mortality and hospital data for internal access only | GPES extract – 98% practice coverage, large subset of codes (4bn items) Community Prescribing | Albasoft ESCRO GP Extraction* Prescribing Information System                      | 80%+ coverage of full longitudinal record, with 100% coverage for COVID codes                      | Enhanced Prescribing Database as proxy   |
| Secondary Care                                 | Census-Mortality-HES linked data asset now available (ONS/NHSD)             | 100% coverage – HES. SUS via DARS extract only, available in TRE soon                         | 100% coverage   | 100% coverage  | Admissions & Discharges  |
| Personal Demographic Service                   | Internal use only   | 100% coverage (via DARS extract only)   | 100% coverage   | 100% coverage  |  |
| Death registry                                 | Provisional Monthly Extract & Linked Census and death occurrence            | 100% coverage Civil Registrations - Deaths  | 100% coverage   | 100% coverage  |  |
| C-19 Infection Survey (CIS)                    | Linked to Test and Trace data   | N/A   | Awaiting DEA accreditation  | Awaiting decision on data access   | Awaiting decision on data access   |
| COVID-19 Clinical Information Network (CO-CIN) | Being linked to 2011 census   | Data for English CO-CIN participants available in Scottish Nation Data Safe Haven             | Limited metadata. Includes English linked data, and COGUK/CO-CIN data asset       | Awaiting decision on data access   | Discussions ongoing to collect data in NI  |
| Census 2011                                    | Household structure   | N/A   |   |  | N/A  |
| Covid Opinions Survey                          |   | N/A   | N/A   | Awaiting decision on data access   | N/A  |
| Business Impact of Covid Survey                | c. 5,000 businesses   | N/A   | N/A   | Awaiting decision on data access   | N/A  |
| Labour Force Survey                            | 40,000 households, 100,000 individuals                                      | N/A   | N/A   | Awaiting decision on data access   | N/A  |
| Intensive Care data                            | HES Critical Care, ICNARC   | HES Critical Care Reviewing IG to share ICNARC.   | SICSAG (updated weekly)   | ICNARC COVID weekly, ICNARC quarterly all admissions and critical care routine data (CCDS) monthly | Critical Care Minimum dataset to be acquired                                     |
| Pillar 3 Testing data (NHS labs)               | Captured within Test and Trace data   | N/A   |   | COVID-19 Test Results  |  |
| Pillar 3 Testing data (iELISA)                 | N/A   | COVID-19 UK Non-hospital Antibody Testing Results (Pillar 3)                                  |   |  | Data to be validated   |
| Other Pillar 4 Testing data                    | VIVALDI, REACT II   |   |   |  |  |
| ZOE Symptom Study App Data                     | Finalising data sharing agreement   |   |   | UK wide (unlinked) Wales (linked)  |  |



# Status of COVID-19 projects using the data – 23 March 2021

6 new research projects now active, taking the total number of active research projects to 310. SAIL have closed 75 project enquiries which did not progress. [20 data access requests covering 83 data assets](#) now submitted via the Gateway for the 12 rapid funded projects. 4 of 12 project requests approved so far.

| # of COVID-19 Projects by stage (change from previous report) | Office for National Statistics Secure Research Service | England (NHS Digital Data Processing Service) | Scotland (National Data Safe Haven) | Wales (SAIL Databank) | Northern Ireland (Honest Broker Service) | Total           |
|---|--|---|-------------------------------------|-----------------------|--|-----------------|
| In development  | 6 (-7)   | 38 (-)  | 36 (-2)                             | 20 (-75)              | 3 (-1)                                   | 103 (-85)       |
| Submitted for Information Governance approval                 | 0 (-5)   | 12 (+2)                                       | 7 (+1)                              | 0 (-)                 | 1 (+1)                                   | 20 (-1)         |
| Approved but not yet active                                   | 6 (+2)   | 4 (+3)  | 8 (-1)                              | 2 (-1)                | 2 (+2)                                   | 22 (+5)         |
| <b>Active research taking place</b>                           | <b>16 (-)</b>  | <b>97 (+2)</b>                                | <b>71 (+2)</b>                      | <b>125 (+2)</b>       | <b>1 (-)</b>                             | <b>310 (+6)</b> |
| Completed projects  | <i>Coming soon</i>                                     | <i>Coming soon</i>                            | <i>Coming soon</i>                  | <i>Coming soon</i>    | <i>Coming soon</i>                       |                 |
| Active Number of Researchers                                  | 273 (+94)  | 52 (-)  | 200 (+6)                            | 249 (+25)             | 1  | 774 (+84)       |
| Average time from application to active research              | 90 days  | <i>Not yet available</i>                      | 9 days                              | 3 days                | <i>Not yet available</i>                 |                 |

## Participation in key UK wide studies:

- [PRINCIPLE](#): 4,613 participants (+2% in last 2 weeks, with continuing data flow of Pillar 2 COVID +ve test results to support recruitment)
- [RECOVERY](#): 39,326 participants across 181 active sites (+2% in last 2 weeks, and +1 active site)
- [CO-CIN \(ISARIC 4C\)](#)
  - 195,253 Tier 0 (case report) (+2% in last 2 weeks)
  - 646 Tier 1 (single sample)
  - 1,659 Tier 2 (serial sampling)
- [GENOMICC](#): 11,940 participants (+3% in last 2 weeks) across 212 ICUs with a total of 5091 intensive care beds
- [COVID-19 ZOE symptom study](#): 4,633,105
- [COG-UK](#): 359,845 viral genomes sequenced (+8% in last 2 weeks)

## Data & Connectivity National Core Study projects now underway.

Examples include:

- [Can phenotypes developed from enhanced remote primary care assessment of COVID-19 be used to identify a cohort of community cases, and enable comparison of recovered and long COVID](#) led by Professor Greenhalgh, University of Oxford
- [How is COVID-19 impacting women and men's working lives in the UK?](#) led by Professor Tracey Warren, University of Nottingham
- [Uptake and comparative safety of new COVID-19 vaccines by age, sex, region, ethnicity, comorbidities, medication, deprivation, risk level and evidence of prior COVID infection](#) led by Professor Hippisley-Cox, University of Oxford

## Data Access Registers

For more information on the active projects:

- [ONS Secure Research Service](#): List of accredited researchers and research projects under the Research Strand of the Digital Economy Act)
- [NHS Digital](#): Register of approved data releases (includes all access)
- [Scotland](#): Public Benefit and Privacy Panel approvals
- [SAIL Databank](#): COVID-19 projects listed on gateway
- [NI Honest Broker Service](#): Projects currently being carried out.